May 2007
BioWorld Today;5/23/2007, Vol. 18 Issue 100, p3
The article offers news briefs on clinical trials. Improvements in symptoms of decreased libido and erectile dysfunction in hypogonadal men were reported by Auxilium Pharmaceuticals Inc. in a retrospective data reported at an American Urological Association meeting. A phase I-data showing BL-1020 was well tolerated was reported by BioLineRx Ltd. at the American Psychiatric Association meeting. A phase II data showing that apremilast achieved the primary endpoint was reported by Celgene Corp.


Related Articles

  • Clinic Roundup.  // BioWorld Today;2/ 5/2013, Vol. 24 Issue 24, p8 

    The article offers news briefs related to biopharmaceutics as of February 5, 2013. Auxilium Pharmaceuticals Inc. has already published its pivotal Phase III IMPRESS' uncorrected proof in "The Journal of Urology." The ininterim analysis of BioLineRx Ltd.'s Phase II/III CLARITY trial for BL-1020...

  • Auxilium Expands its ED Presence In U.S. and Canada with Stendra Deal. Powers, Marie // BioWorld Today;10/14/2013, Vol. 24 Issue 197, p1 

    The article reports on a potential 300 million U.S. dollar marketing deal entered by Auxilium Pharmaceuticals Inc. with Vivus Inc. to supply the erectile dysfunction (ED) drug Stendra (avanafil) to its U.S. and Canada market. Stendra, a phosphodiesterase-5 inhibitor (PDE5-i), boasts of faster...

  • CLINIC ROUNDUP.  // BioWorld Today;5/5/2008, Vol. 19 Issue 87, p3 

    This section offers news briefs on clinical trials results released by biopharmaceutical companies as of May 5, 2008. BioLineRx Ltd. has released data demonstrating the effectiveness of the drug BL-1020. Celgene Cellular Therapeutics has announced the successful transplantation of human...

  • Clinic Roundup.  // BioWorld Today;3/10/2011, Vol. 22 Issue 47, p2 

    This section offers news briefs related to biotechnology firms as of March 2011, including the submission of an investigational new drug application to the U.S. Food and Drug Administration (FDA) by Adamis Pharmaceuticals Corp., the status of Auxilium Pharmaceutical Incorporated's study of...

  • Clinic Roundup.  // BioWorld Today;3/26/2013, Vol. 24 Issue 59, p4 

    This section offers news briefs concerning drug clinical trials. Auxilium Pharmaceuticals Inc. reported positive data from the Phase IIa open-label study of Xiaflex therapeutic safety in adhesive capsulitis. OncoSec Medical Inc. posted positive response results from its Phase II clinical trial...

  • Vivus, Auxilium Gain On Impotence Drug Deal. AMY REEVES // Investors Business Daily;10/11/2013, p00 

    Shares of drugmakers

  • Phase II Clinical Trials Update: September 2013.  // BioWorld Insight;10/14/2013, Vol. 21 Issue 42, p12 

    A table is presented which lists the biotechnology companies' phase II clinical trials updates as of September 2013 which includes Agenus Inc., Biolinerx Ltd., and Aesrx LLC.

  • XIAFLEX EFFECTIVE IN NONSURGICALLY TREATING MP/PIP JOINTS.  // Worldwide Biotech;Jan2011, Vol. 23 Issue 1, p6 

    This article reports on the publication of the pivotal CORD II phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum) conducted by Auxilium Pharmaceuticals Inc. in 2010. The company announced the publication of the trial in the December 2010 online edition of "The Journal of...

  • Clinic Roundup.  // BioWorld Today;9/7/2011, Vol. 22 Issue 173, p9 

    This section offers news briefs related to clinical trials. AB Science SA of Paris, France recruited the first patient in a study of protein kinase inhibitor masitinib in a primary progressive multiple sclerosis. AiCuris GmbH & Co. of Germany said that a resistance analysis from a trial of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics